A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Alpelisib (Primary) ; Aromatase inhibitors (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- 04 Sep 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Sep 2024.
- 02 Jul 2024 Planned primary completion date changed from 1 May 2024 to 1 Jul 2024.
- 26 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 May 2024.